The FDA granted approval to Abbott’s NDA for Simcor, a fixed-dose combination of Niaspan (extended-release niacin) and simvastatin, the generic version of Merck’s Zocor. The drug is indicated to raise ...
SIMCOR is the first treatment to combine Abbott's proprietary niacin extended-release and simvastatin, the most commonly used statin. SIMCOR is a prescription medication used along with diet in people ...
Niacin extended-release 500 mg, simvastatin 20 mg; tabs. Simcor combines the HMG-CoA reductase inhibitor, simvastatin, and the nicotinic acid derivative, extended-release niacin (Niaspan, also from ...
Abbott announced that it has received FDA approval for two new dosage strengths of Simcor (niacin extended-release/simvastatin tablets). The two new dosages strengths ...
Abbott's new combination heart pill Simcor has positive effects on ‘good’ and ‘bad’ cholesterol as well as triglycerides and other key lipids that lead to coronary disease, according to results ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. (Reuters) - Abbott Laboratories asked a federal court to ...
FDA approves Simcor for cholesterol treatment Abbott has received FDA approval for Simcor, a fixed-dose, single-pill combination of two cholesterol-lowering medications: Niaspan (niacin ...
MORRISTOWN, N.J., May 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida ...
Abbott Laboratories has received approval from US regulators for Simcor, the latest combination drug to be given the go-ahead as a treatment for cholesterol. Abbott Laboratories has received approval ...
Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR(R) (niacin extended-release/simvastatin)
ABBOTT PARK, Ill., Dec. 10 Abbott (NYSE: ABT) has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR®, a ...
ABBOTT PARK, Ill., July 28 Abbott (NYSE: ABT) today received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results